

STATISTICAL PLAN

Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism

NCT02525796

7/31/2015

## Statistical Plan

**Analytic Plan, Sample Size and Power:** A sample size of 20 subjects per intervention arm (n=60 total) has been chosen using conservative calculations. The **primary outcome**,  $\Delta$ PTH in response to randomized drug therapy, will be analyzed using a 2-arm ANOVA analysis evaluating the difference between EPL and placebo. A 3-arm ANOVA including the amiloride arm will also be conducted. Sample size calculations are presented in **Figure** using preliminary data from the RAAS-PARC study where the  $\Delta$ PTH= -13 pg/mL was seen with RAAS inhibition in participants with P-HPTH, but also using a more conservative estimate (-9.0 pg/mL) that is 25% lower. It is expected that  $\Delta$ PTH with placebo will range from 0 to +4.57 pg/mL, and calculations have been made to anticipate that amiloride may serve as either a negative control (like placebo) or positive control (like EPL). With these conservative estimates, a sample size of 20 subjects/arm will be sufficient to demonstrate a  $\Delta$ PTH with a type I error of <0.05 and power=80%.

The **secondary outcomes**, change in calcium, will be analyzed in the same fashion as PTH. For calcium, sample size calculations are based on decreases in *total calcium* seen in the RAAS-PARC study ( $\Delta$ Ca= -0.32 mg/dL); treatment with EPL is expected to result in a much greater effect estimate. Thus, using *conservative* estimates of  $\Delta$ Ca= -0.20 to -0.32 mg/dL, a sample size of 20 subjects per intervention arm will be sufficient to achieve 80% power.

**Figure:** Sample size calculations based on  $\Delta$ PTH.

	$\Delta$ PTH	$\Delta$ PTH	$\Delta$ PTH	SD	Sample Size per Arm	
	Placebo	Amiloride	SPIRO		PWR=0.8	PWR=0.9
2-arms	0 pg/mL	-	-9.0 pg/mL	9.4	19	24
	0 pg/mL	-	-13.0 pg/mL	9.4	10	13
	0 pg/mL	0 pg/mL	-9.0 pg/mL	9.4	17	22
	0 pg/mL	0 pg/mL	-13.0 pg/mL	9.4	9	11
	0 pg/mL	-6.5 pg/mL	-13.0 pg/mL	9.4	12	15
	0 pg/mL	-9.0 pg/mL	-13.0 pg/mL	9.4	11	14
3-arms	0 pg/mL	-13.0 pg/mL	-13.0 pg/mL	9.4	9	11

**Figure:** Sample size calculation based on  $\Delta$ Ca.

	$\Delta$ Ca	$\Delta$ Ca	$\Delta$ Ca	SD	Sample Size per Arm	
	Placebo	Amiloride	SPIRO		PWR=0.8	PWR=0.9
	0 mg/dL	0 mg/dL	-0.20 mg/dL	0.21	17	22
	0 mg/dL	0 mg/dL	-0.32 mg/dL	0.21	8	10